• Latest Posts
In Depth 1 Jun 2020

How Personal Genomics Companies Are Changing Drug Development

AI Drug Discovery Firm Exscientia Closes €54M Series C

Argenx Follows up Phase III Success with Giant €785M Global Offering

Spanish Neurology Biotech Launches with €7.6M Series A

French Startup Secures €2.3M to Advance Cancer RNA Immunotherapy

MSD Enters Covid-19 Vaccine Race by Acquiring Themis Bioscience

ADVERTISEMENT

‘Just Add Water’ GM Mosquitoes Suppress Wild Population by 95%

Expert Advice 27 May 2020

Why Listening to Patient Organizations is Key in Drug Development

Argenx’s Rare Disease Treatment Strikes Gold in Phase III

In Depth 25 May 2020

Could Cell Therapy Target the Symptoms of Severe Covid-19?

Evonik and Beiersdorf Team Up to Turn CO₂ into Skin Care Products

Phase II Fail Ends Swiss-US Drug for Rare Kidney Disease

ADVERTISEMENT